Table 1.
Use of B. lactis HN019™, including probiotic blends, in human clinical trials published until December 2020.
| Daily dose of B. lactis HN019™ (total probiotic potency in blend, CFU) | Subjects receiving products containing B. lactis HN019™ (N) | Age of subjects (median/mean, years) | Duration of supplementation (week) | Product format (delivery vehicles) | Other ingredients used in serum | Reference |
|---|---|---|---|---|---|---|
| Influence on digestive system | ||||||
| 2 × 108-109 (8 × 108-109) | 25 Healthy elderly |
65–90 (75.3) | 24 | NR (powder) | L. paracasei Lpc-37, L. rhamnosus HN001, L. acidophilus NCFM, FOS | (18) |
| NR/5 × 109 | 27 Adult constipation |
19–70 (25.7) | 30 days | Capsule | L. acidophilus NCFM, L. casei Lc-11, Lactococcus lactis Ll-23, B. bifidum BB-06 | (19) |
| 1–2 × 109 (6–12 × 109) | 42 Constipated adult women |
22–60 (36.84) | 6 | Sachet (water) | L. rhamnosus SP1 100MLD, L. casei F19, L. acidophilus La-14, B. longum BB536, B. bacterium brief M-16V, inulin | (20) |
| 1010 (2.75 × 1010) | 78 FC or IBS-C |
18–70 (NR) | 2 | Capsule (drink and food) | L. paracasei Lpc-37, L. acidophilus NCFM, B.lactis Bl-04, B.lactis Bi-07 | (21) |
| High dose: 1 × 1010
Low dose: 1 × 109 |
152 Constipation |
18–70 (41.7) | 4 | Capsule (yogurt) | NA | (22) |
| 1 × 109 | 14 Healthy female colleague students |
>18 (NR) | 2 | Sachet (water or milk) | NA | (23) |
| 5 × 109 | 130 Healthy Preschool children |
2–4 (38 months) | 9 months | Capsule (milk) | NA | (24, 25) |
| 109 (2 × 109) |
Constipated young adults |
18–45 (31.5) | 2 | Yogurt | Polydextrose, L. acidophilus NCFM | (26) |
| NR (2 × 108-109) | 50 Constipation adults |
18–65 (NR) | 30 days | Sachet (water) | L. paracasei Lpc-37, L. rhamnosus HN001, L. acidophilus NCFM, FOS | (27) |
| 1.9 × 107 | 312 Healthy children |
1–4 (21.7 months at baseline) | 1 year | Reconstituted milk | GOS | (28–30) |
| 2.17 × 107-4.88 × 107 | 80 Healthy full-term Infants |
2–6 weeks (NR) | 1 year | Infant formula | Gangliosides, FOS, long-chain polyunsaturated fatty acids | (31) |
| High dose: 1.72 × 1010
Low dose: 1.8 × 109 |
66 Adult constipation |
25–65 (44 in high dose, 44 in low dose) | 2 | Capsule (yogurt) | NA | (32) |
| Modulation of immune system | ||||||
| 2 × 108-109 (8 × 108-109) | 25 Healthy elderly |
65–90 (75.3) | 24 | Powder (NR) | L. paracasei Lpc-37, L. rhamnosus HN001, L. acidophilus NCFM, FOS | (33)c |
| 1 × 107 | 69 Pregnant women |
18–35 (29.4) | 8–12 weeks of gestation to the end of pregnancy | Reconstituted milk | NA | (34) |
| 9 × 109 | 171 Infants at risk of allergies |
2–16 days at baseline (6 days) | Mothers: Pregnancy week 35 to 6 m post-partum, if breast feeding, and children: 2 years | Capsule (water, formula, breast milk, or food) | NA | (35–42)b |
| 9 × 109 | 35 Mother-baby pairs |
Mother: NR Infant: 2–16 days at baseline (6 days) |
Mothers: 2–5 weeks before delivery to 6 m post-partum, if breast feeding, and children: 2 years | Capsule (NR for mother, but in water, formula, breast milk, or food for infants) | NA | (43)b |
| 2 × 1010a | 29 Children with atopic eczema |
1–10 (3.8) | 12 | Powder (drink or food) | L. rhamnosus HN001 | (44) |
| 5 × 109 | 14 Health elderly |
60–84 (69.5) | 3 | Sachet (milk) | NA | (45) |
| High dose: 5 × 1010
Low dose: 5 × 109 |
30 Healthy elderly |
63–84 (46) | 3 | Reconstituted milk | NA | (47) |
| 5 × 1010 | 50 Healthy middle-aged subjects |
41–81 (48) | 3 | Reconstituted milk | NA | (49) |
| 3 × 1011 | 13 Healthy elderly |
62–83 (50) | 6 | Reconstituted milk | NA | (51) |
| Other gut health-related benefits | ||||||
| High dose: 3 × 109 (2 × 1010) Low dose: NR (1 × 1010) |
14 C-section-delivered neonates |
0 | 4 | NR (breastmilk) | B. lactis Bi-07, L. rhamnosus HN001, GOS | (52) |
| 2 × 108-109 (8 × 108-109) | 25 Healthy elderly |
65–90 (75.3) | 24 | Powder (NR) | L. paracasei Lpc-37, L. rhamnosus HN001, L. acidophilus NCFM, FOS | (53)c |
| 9 × 109 | 171 Infants at risk of allergies |
2–16 days at baseline (6 days) | Mothers: pregnancy week 35 to 6 m post-partum, if breast feeding, and children: 0–2 years | Capsule (water, formula, breast milk, or food) | NA | (54, 55) c |
| NR (2 × 109) | 73 CRC patients undergone colorectal resection |
NR (60.9) | 7 days | Powder (water) | L. paracasei Lpc-37, L. rhamnosus HN001, L. acidophilus NCFM, FOS | (56) |
| 2 × 109 (8 × 109) | 49 CRC patients undergone surgery |
NR (64.5) | 5 days prior to surgery and for 14 days after surgery | Sachet (NR) | L. paracasei Lpc-37, L. rhamnosus HN001, L. acidophilus NCFM, FOS | (57) |
| High dose: 5 × 109
Medium dose: 1 × 109 Low dose: 6.5 × 107 |
60 Healthy elderly |
60–87 (67 in high dose, 70 in medium/dose) | 4 | Reconstituted milk | NA | (58) |
| 3 × 1010 | 10 Healthy adults |
20–60 (NR) | 4 | Reconstituted milk | NA | (59) |
| Non-gut health related benefits | ||||||
| 108-1010 | 20 Chronic periodontitis patients |
>30 (NR) | 30 days | Lozenge | NA | (60) |
| 109 (4 × 109) | 19 Hypertensive women |
34–50 (43.3) | 8 | Sachet (NR) | L. paracasei Lpc-37, L. rhamnosus HN001, L.acidophilus NCFM | (61) |
| 2.72 × 1010 | 19 Metabolic syndrome |
18–60 (48.05) | 90 days | Fermented milk | NA | (62) |
| 2.72 × 1010 | 26 Metabolic syndrome |
18–60 (NR) | 45 days | Fermented milk | NA | (63) |
CFU, colony forming unit; CRC, colorectal cancer; FOS, fructo-oligosaccharide; FC, functional constipation; IBS-C, constipation dominant irritable bowel syndrome; GOS, galacto-oligosaccharide; NA, not applicable; NR, not reported.
a
The article only mentioned CFU/g, but not the g for the finished format.
b
Studies published from the same cohort first described in Wickens et al. (36).
c
Studies published from the same cohort first described in de Carvalho et al. (33).